title: Advances in cardiology: clinical trial update.
abstract: Multiple key cardiology trials have been presented or published over recent months, several with the potential to change clinical practice. In this article, we summarize and place in clinical context new trial findings regarding anticoagulation in the cardiac catheterization laboratory (enoxaparin, fondaparinux and unfractionated heparin), the implications of genetic polymorphisms and functional testing for antiplatelet therapy (clopidogrel and ticagrelor), new oral anticoagulants for use in atrial fibrillation (apixiban and rivaroxaban), optimal pacing strategies and pharmacological agents in heart failure (ivabradine, eplerenone, cardiac resynchronization therapy, telemonitoring and intracoronary bone marrow stem cell infusion). Clinical trials in percutaneous structural intervention (transcatheter aortic valve implantation, MONARC™ mitral annular implant, STARFlex(®) patent foramen ovale device) and advanced percutaneous coronary intervention (everolimus-eluting stents, biodegradable polymer/polymer-free technologies and contemporary use of intravascular ultrasound) are also discussed.
authors.affiliation: Craigavon Cardiac Centre, Southern Trust, Northern Ireland, BT63 5QQ, UK.
authors.forename: Andrew J
authors.initials: AJ
authors.lastname: Howe
authors.forename: James A
authors.initials: JA
authors.lastname: Shand
authors.forename: Ian B A
authors.initials: IB
authors.lastname: Menown
mesh_terms: D015906:Angioplasty, Balloon, Coronary; D000925:Anticoagulants / Q000627:therapeutic use*; D001281:Atrial Fibrillation / Q000188:drug therapy; D002309:Cardiology / Q000639:trends*; D003324:Coronary Artery Disease / Q000188:drug therapy* / Q000601:surgery / Q000628:therapy; D015949:Factor IXa / Q000037:antagonists & inhibitors; D005343:Fibrinolytic Agents / Q000627:therapeutic use; D000077425:Fondaparinux; D006495:Heparin, Low-Molecular-Weight / Q000627:therapeutic use; D006801:Humans; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D011110:Polymorphism, Genetic; D011134:Polysaccharides / Q000627:therapeutic use; D015607:Stents
chemical_list: D000925:Anticoagulants; D005343:Fibrinolytic Agents; D006495:Heparin, Low-Molecular-Weight; D010975:Platelet Aggregation Inhibitors; D011134:Polysaccharides; D015949:Factor IXa; D000077425:Fondaparinux